By Fineline Cube 
Japan-based Terumo Corporation (TYO: 4543) has entered into an agreement with China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) to acquire the latter’s drug product plant in Leverkusen, Germany, for EUR 150 million (USD 168 million). This strategic move aims to enhance Terumo’s production capacity and global responsiveness by utilizing the newly acquired facility as its first overseas CDMO production base. This acquisition is expected to accelerate the global expansion of Terumo’s CDMO business.
Terumo’s Business Scope
Terumo is known for developing containers such as prefilled syringes and drug delivery devices using materials suitable for pharmaceutical applications. Additionally, the company engages in the CDMO business for combination products of pharmaceuticals and medical devices, leveraging advanced manufacturing technologies.-Fineline Info & Tech